Consulted for Seed-stage biotech companies with novel therapeutic modalities, seeking to raise their Series A round. Focused on corporate strategy, pipeline definition and fundraising pitch. Identified indications and patient populations where the extrapolated therapeutic advantage of the platform is clear when compared to existing modalities. Constructed a portfolio that prioritizes derisking the novel platform with the first two programs, with commercial upside following.

Led Northpond Labs, the research and development-focused affiliate of Northpond Ventures, including our collaborations with the Wyss Institute, MIT and Stanford.Served as Director on the Boards of Aro Biotherapeutics, Artisan Bio, EnPlusOne, Isolere Bio (acquired Feb 2023), Garuda Therapeutics, Triumvira Immunologics and Walking Fish Therapeutics.

I led Scientific and General Operations, Program Management, Corporate Development, Strategy, Business Development and Alliance Management.

I led Corporate Development, Strategy, Business Development and Alliance Management.

I identified, evaluated and negotiated agreements to access promising therapeutics and technologies, including: i) defining the strategic landscape for opportunities aligned with Juno’s corporate interests, ii) leading diligence and planning teams to assess opportunities and iii) leading negotiation teams in drafting and executing term sheets and contracts with potential partners.

I identified early-stage (pre-clinical proof-of-concept) innovation at academic institutions, start-up biotech companies and venture capital firms. I coordinated the evaluation, funding and subsequent on-boarding of new science aligned with JJIC's overall strategic vision for therapeutics, medical devices, diagnostics and consumer healthcare.

I sourced and assessed investment opportunities for mid-stage (post proof-of-concept) life-science companies. My remit included therapeutics, medical devices and diagnostics that address chronic diseases (GI, CNS and diabetes). I developed an investment roadmap for personalised medicine, which encompassed strategies to address prognostics, diagnostics and treatment decision support.

I managed the on-site research operations to prepare our stem cell regenerative medicine platform for clinical trials. My remit included driving the strategic agenda for the business with the other members of the Executive Team, providing overall project management to the research teams and leading the experimental design for our wound healing product.

I focused primarily on two industries, Pharma and Private Equity. Within Pharma I have experience in Commercial, R&D, Business Development and Corporate Strategy. Within Private Equity I performed commercial due diligence on targets across sectors including High Tech, Consumer Goods, Medical Devices and Pharma.

I led the development of a novel drug discovery platform based on my patented Ph.D. work on targeted protein degradation.